Literature DB >> 29335273

Establishing an Evidence-Based Method to Diagnose Cardiac Sarcoidosis: The Complementary Use of Cardiac Magnetic Resonance Imaging and FDG-PET.

Edward J Miller1, Daniel A Culver2.   

Abstract

Entities:  

Keywords:  Editorials; heart block; idiopathic pulmonary fibrosis; magnetic resonance imaging; patient care; sarcoidosis

Mesh：

Substances：

Year:  2018        PMID： 29335273     DOI： 10.1161/CIRCIMAGING.117.007408

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN： 1941-9651            Impact factor:   7.792


× No keyword cloud information.
  5 in total

1.  A case series on inflammatory cardiomyopathy and suspected cardiac sarcoidosis: role of cardiac PET in management.

Authors:  Peter J Kennel; Farhan Raza; Jiwon Kim; Parmanand Singh; Alain Borczuk; Udhay Krishnan; Maria Karas; Irina Sobol
Journal:  Eur Heart J Case Rep       Date:  2020-08-03

Review 2.  Updates on the Role of Imaging in Cardiac Sarcoidosis.

Authors:  Yan Yatsynovich; Damian Valencia; Mikhail Petrov; Juan David Linares; Mufti M Rahman; Nathaniel Dittoe
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-08-07

3.  Non-steroidal treatment of cardiac sarcoidosis: A systematic review.

Authors:  Cesia Gallegos; Evangelos K Oikonomou; Alyssa Grimshaw; Mridu Gulati; Bryan D Young; Edward J Miller
Journal:  Int J Cardiol Heart Vasc       Date:  2021-04-29

4.  Incidence of Sudden Cardiac Death and Life-Threatening Arrhythmias in Clinically Manifest Cardiac Sarcoidosis With and Without Current Indications for an Implantable Cardioverter Defibrillator.

Authors:  Hanna-Kaisa Nordenswan; Pauli Pöyhönen; Jukka Lehtonen; Kaj Ekström; Valtteri Uusitalo; Meri Niemelä; Tapani Vihinen; Kari Kaikkonen; Petri Haataja; Tuomas Kerola; Tuomas T Rissanen; Aleksi Alatalo; Päivi Pietilä-Effati; Markku Kupari
Journal:  Circulation       Date:  2022-08-24       Impact factor: 39.918

Review 5.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.